Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ropinirole
Drug ID BADD_D01966
Description Ropinirole, also known as _ReQuip_, is a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome [FDA label], [A174547]. It is manufactured by GlaxoSmithKline Pharmaceuticals. Ropinirole was initially approved in 1997 by the FDA [FDA label] for the management of Parkinson's disease. In 2005, it was the first drug approved in the US for the management of primary moderate to severe restless legs syndrome [A174547]. In 2008, the extended-release capsules of ropinirole were approved, allowing for less frequent dosing, therefore increased compliance, and offering a similar side effect profile and efficacy to previous formulations of ropinirole [A35711].
Indications and Usage For the treatment of the signs and symptoms of idiopathic Parkinson's disease. Also used for the treatment of restless legs syndrome.
Marketing Status Prescription; Discontinued
ATC Code N04BC04
DrugBank ID DB00268
KEGG ID D08489
MeSH ID C046649
PubChem ID 5095
TTD Drug ID D0R9EQ
NDC Product Code 43353-267; 55111-727; 43353-265; 0228-3660; 46708-262; 60429-822; 10135-677; 0228-3659; 68462-259; 0378-5505; 10135-676; 16729-238; 43353-258; 50090-4684; 55111-662; 50090-5167; 71335-1188; 71335-0064; 60429-818; 50090-4803; 10135-673; 68462-258; 43353-266; 68462-254; 46708-265; 71335-1231; 62332-109; 68462-257; 0228-3640; 0378-5502; 46708-264; 58032-1011; 0781-5786; 60429-821; 0378-5504; 16729-237; 10135-678; 70518-2439; 10135-679; 55111-659; 50090-2068; 71335-1982; 16729-233; 46708-266; 72189-222; 16729-232; 0378-5501; 0378-5503; 68462-253; 60429-817; 60429-823; 68462-255; 16729-235; 62332-108; 55111-661; 70518-2750; 60429-819; 55111-728; 0378-5525; 0781-5784; 0228-3658; 16729-234; 63629-8123; 10135-674; 10135-675; 68462-256; 61919-780; 0378-5550; 62332-110; 60429-820; 71335-1167; 62332-107; 0228-3661; 16729-236; 46708-263; 0781-5780; 0781-5788; 62332-111; 0781-5782
Synonyms ropinirole | 4-(2-(di-n-propylamino)ethyl)-2(3H)-indolone | ropinirol | SK&F 101468 | SKF 101468 | SK&F-101,468 | Requip | ropinirole hydrochloride
Chemical Information
Molecular Formula C16H24N2O
CAS Registry Number 91374-21-9
SMILES CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal adhesions12.02.03.006; 07.07.03.001--Not Available
Abdominal discomfort07.01.06.001--Not Available
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.0020.001281%
Abdominal pain lower07.01.05.010--Not Available
Abdominal pain upper07.01.05.003--
Abdominal rigidity07.01.05.0110.000427%Not Available
Abnormal dreams19.02.03.001; 17.15.02.0010.000640%Not Available
Abnormal faeces07.01.03.0010.000427%Not Available
Abscess11.01.08.001--Not Available
Accommodation disorder06.02.04.001--Not Available
Acidosis14.01.03.002--
Acne23.02.01.001--Not Available
Actinic keratosis23.01.06.001--Not Available
Acute psychosis19.03.01.0010.001281%Not Available
Adenocarcinoma16.16.01.004--Not Available
Aggression19.05.01.0010.001494%Not Available
Agitation19.06.02.001; 17.02.05.0120.001067%
Agranulocytosis01.02.03.001--Not Available
Alanine aminotransferase increased13.03.01.003--
Albuminuria20.02.01.001--Not Available
Alcohol abuse19.07.02.0070.000427%Not Available
Alcoholism19.07.02.0010.000111%Not Available
Alopecia23.02.02.001--
Altered state of consciousness19.07.01.003; 17.02.04.0010.000640%Not Available
Amenorrhoea05.05.01.002; 21.01.02.001--
Amnesia19.20.01.001; 17.03.02.001--
Amylase increased13.05.01.009--
Anaemia01.03.02.001--
Anaemia vitamin B12 deficiency14.12.02.001; 01.03.01.001--Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 25 Pages